Aeterna Zentaris Completes Phase 3 DETECT-Trial For Macimorelin In Diagnosing Childhood Onset Growth Hormone Deficiency; Top-Line Data And Full Study Results Expected In Q3 2024
Portfolio Pulse from Benzinga Newsdesk
Aeterna Zentaris has completed its Phase 3 DETECT-Trial for Macimorelin, aimed at diagnosing childhood onset growth hormone deficiency. Top-line data and full study results are expected in Q3 2024.
June 13, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aeterna Zentaris has completed its Phase 3 DETECT-Trial for Macimorelin, which is aimed at diagnosing childhood onset growth hormone deficiency. The top-line data and full study results are expected in Q3 2024.
The completion of a Phase 3 trial is a significant milestone for any biotech company. Investors will likely view this as a positive development, anticipating potential approval and commercialization of Macimorelin. The expectation of top-line data in Q3 2024 adds a timeline for potential future gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100